Navigation Links
Perceptive Informatics Improves Clinical Site Monitoring Access and Flexibility With Portable USB Drive Capability

BOSTON, April 14 /PRNewswire-FirstCall/ -- Perceptive Informatics, the technology subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), today announced the availability of its clinical site management and monitoring software, IMPACT(R) MySites, on a portable USB drive. Clinical monitors can now securely upload site visit information onto the USB drive, without carrying their laptop computers with them. The MySites monitoring solution is a part of the IMPACT suite, Perceptive Informatics' market-leading Clinical Trial Management System (CTMS).

"We expect that clinical monitors will benefit from increased flexibility, productivity, and efficiency with the option to easily and securely capture site visit information from anywhere in the world at any time, using the new portable functionality of the IMPACT MySites USB drive," said Todd Joron, Corporate Vice President and General Manager of Perceptive Informatics at PAREXEL. "This capability represents an important step toward a truly mobile eClinical environment."

The IMPACT MySites module supports on-line and off-line monitoring activities and the collection of associated data during site visits by clinical monitors in the field. With the USB drive capability, IMPACT MySites is a zero-footprint solution, requiring no software installation. As the entire MySites module is housed on the USB drive, information collected by clinical monitors is securely stored and later synchronized with the IMPACT database.

The Perceptive Informatics IMPACT system has more than 26,000 users in over 85 countries -- the largest number of users of any CTMS solution on the market. Biopharmaceutical companies rely on the IMPACT solution, which enables complete trial management and planning, to manage, track, and organize clinical trial management data. Perceptive's IMPACT software interfaces with Interactive Voice and Web Response Systems (IVRS/IWRS) as well as electronic data capture (EDC) and data management applications, in addition to financial reporting.

About Perceptive Informatics, a PAREXEL Company

PAREXEL's Technology Division, Perceptive Informatics, combines clinical knowledge, quality and regulatory experience with advanced technology to decrease time to market, risk and cost associated with clinical trials. Perceptive's portfolio includes Medical Imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS & IWRS), and Integration Services as well as web-based portal solutions, tracking tools, electronic diaries and investigator database solutions. Perceptive offers medical imaging services to rapidly and objectively assess the safety and efficacy of new drugs, biologics and medical devices in clinical trials. The IMPACT(R) solution is Perceptive's market-leading CTMS product with 26,000 users worldwide, and Perceptive's INITIATOR(TM) trial management product targets the needs of Phase I units. For more information about Perceptive Informatics, visit

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 64 locations throughout 51 countries around the world, and has more than 7,300 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended December 31, 2007 as filed with the SEC on February 7, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL and IMPACT are registered trademarks of PAREXEL International Corporation, and PERCEPTIVE INFORMATICS is a registered trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.


Jennifer Baird

Senior Director of Public Relations Rebecca Passo

PAREXEL International SHIFT Communications

Tel: +781-434-4409 Tel: +617-779-1817

Email: Email:

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. IC Sciences Launches ICS Alliance to Advance Development and Adoption of Informatics Instruments for Next Generation Healthcare
2. Core Informatics Completes Successful LIMS Implementation for Progenics Pharmaceuticals
3. BioInformatics, LLC Studies Trade Show Exhibition Strategies in the Life Science Market
4. Malaysia Genome Institute Advances Bioinformatics Research Using SGI Technology
5. Method to deliver molecules within embryonic stem cells improves differentiation
6. Special coating greatly improves solar cell performance
7. Indivumed Appoints Annette Kassen as Vice President Clinical Research
8. International Federation of Clinical Chemistry Forms Partnership With the Labs Are Vital(TM) Initiative
9. PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacology Business
10. Touch Bionics appoints Head of Clinical Advocacy
11. Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary Apte, ... their initial angel funding process. Now, they are paying it forward to other ... stage investments in the microbiome space. In this, they join other successful ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ... today reported financial results for the quarter ended ... expressed in Canadian dollars and presented under International ... United States ," said Andrew Rae ... advancements regarding iCo-008 are not only value enriching ...
(Date:11/24/2015)... 2015 --> ... "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, ... DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) ... market is expected to reach USD 1,918.6 Million by ... CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... Israel , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... on December 29, 2015 at 11:00 a.m. Israel ... Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... of Eric Paneth and Izhak Tamir to the ... Rami Skaliter as external directors; , approval of an amendment to ...
Breaking Biology Technology:
(Date:10/27/2015)... NEW YORK , Oct. 27, 2015 ... the major issues of concern for various industry verticals ... This is due to the growing demand for secure ... practices in various ,sectors, such as hacking of bank ... concerns for electronic equipment such as PC,s, laptops, and ...
(Date:10/27/2015)... , Oct. 27, 2015 Synaptics Inc. (NASDAQ: ... announced that Google has adopted the Synaptics ® ... solutions to power its newest flagship smartphones, the Nexus ... --> --> ... to provide strategic collaboration in the joint development of ...
(Date:10/26/2015)... PALO ALTO, Calif. and LAS ... – Nok Nok Labs , an innovator in ... FIDO Alliance , today announced the launch of its ... the first unified platform enabling organizations to use standards-based ... authentication. The Nok Nok S3 Authentication Suite is ideal ...
Breaking Biology News(10 mins):